chlorambucil has been researched along with lenalidomide in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Blonski, JZ; Chanan-Khan, A; Desjardins, P; Dolan, S; Echeveste, MA; Egyed, M; Golany, N; Gribben, JG; Martinelli de Oliveira, FA; Mei, J; Robak, T; Zhang, J | 1 |
| Ferrajoli, A; Vitale, C | 1 |
| Bellido, M; Chamuleau, MED; de Boer, F; Dobber, JA; Doorduijn, JK; Hoogendoorn, M; Kater, AP; Kerst, JM; Kersting, SS; Koene, HR; Langerak, AW; Levin, MD; Marijt, EWA; Posthuma, WFM; Raymakers, RAP; Saberi Hosnijeh, F; Schaafsma, MR; Te Raa, GD; Tonino, SH; van der Straten, L; van Gelder, M; van Oers, MHJ | 1 |
1 review(s) available for chlorambucil and lenalidomide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for chlorambucil and lenalidomide
| Article | Year |
|---|---|
Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial).
Topics: Aged; Antineoplastic Agents; Chlorambucil; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Survival Analysis; Thalidomide | 2017 |
Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Chlorambucil; Disease-Free Survival; Female; Gene Expression; Humans; Immunoglobulin Heavy Chains; Immunotherapy; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Prognosis; Proteinase Inhibitory Proteins, Secretory; Proteomics; Receptors, IgE; Rituximab; Signaling Lymphocytic Activation Molecule Family; Treatment Outcome; Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2020 |
2 other study(ies) available for chlorambucil and lenalidomide
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Lenalidomide can be safely combined with chlorambucil and rituximab in older patients with chronic lymphocytic leukemia.
Topics: Aged; Chlorambucil; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Treatment Outcome | 2019 |